Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $5.2 million.

  • Ani Pharmaceuticals' Gains from Investment Securities changed N/A to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 573.43%. This contributed to the annual value of $5.3 million for FY2024, which is 1340.4% up from last year.
  • Ani Pharmaceuticals' Gains from Investment Securities amounted to $5.2 million in Q3 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Gains from Investment Securities peaked at $5.3 million during Q1 2024, and registered a low of -$1.1 million during Q2 2022.
  • Its 5-year average for Gains from Investment Securities is $2.0 million, with a median of $833000.0 in 2021.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 24092.66% in 2022, then surged by 51086.76% in 2023.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Gains from Investment Securities stood at $774000.0 in 2021, then surged by 219.9% to $2.5 million in 2022, then plummeted by 91.28% to $216000.0 in 2023, then soared by 2375.46% to $5.3 million in 2024, then decreased by 1.93% to $5.2 million in 2025.
  • Its Gains from Investment Securities stands at $5.2 million for Q3 2025, versus $5.3 million for Q1 2024 and $216000.0 for Q4 2023.